market-trends is the sole category represented across all 1 tracked stories. CyPath Lung is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Each carries 2 original sources on average. We currently track 1 Healthcare story that mention Gordon Downie, all published on July 8, 2026.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Gordon Downie
market-trends is the sole category represented across all 1 tracked stories. CyPath Lung is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Each carries 2 original sources on average. We currently track 1 Healthcare story that mention Gordon Downie, all published on July 8, 2026.
Stories tracked
1
Sources per story
2
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 4 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Gordon Downie. Shared-story counts are live from our verified record — not editorial picks.
bioAffinity Technologies reported a record Q2 for its CyPath® Lung noninvasive test, with sales more than doubling year-over-year and physician adoption accelerating. The test, designed to help evaluate indeterminate lung nodules, has now been used nearly 3,000 times across pulmonology and VA settings. The trend underscores the demand for noninvasive early cancer diagnostics in an expanding screening population.
